<bill session="107" type="h" number="1530" updated="2013-07-14T18:57:35-04:00">
  <state datetime="2001-04-04">REFERRED</state>
  <status>
    <introduced datetime="2001-04-04"/>
  </status>
  <introduced datetime="2001-04-04"/>
  <titles>
    <title as="introduced" type="short">Prescription Drug Competition Act of 2001</title>
    <title as="introduced" type="official">To ensure the timely availability of generic drugs through enhancement of drug approval and antitrust laws enforced by the Food and Drug Administration and the Federal Trade Commission regarding brand name drugs and generic drugs.</title>
  </titles>
  <sponsor id="400425"/>
  <cosponsors>
    <cosponsor id="400026" joined="2001-04-04"/>
    <cosponsor id="400050" joined="2001-04-04"/>
    <cosponsor id="400103" joined="2002-01-29"/>
    <cosponsor id="400106" joined="2001-04-04"/>
    <cosponsor id="400387" joined="2001-04-04"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2001-04-04">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2001-04-04">
      <text>Referred to House Energy and Commerce</text>
    </action>
    <action datetime="2001-04-04">
      <text>Referred to House Judiciary</text>
    </action>
    <action datetime="2001-04-25">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Energy and Commerce"/>
    </action>
    <action datetime="2001-10-11">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR S10642-10643"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
    <committee code="HSJU" name="House Judiciary" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Commerce"/>
    <term name="Actions and defenses"/>
    <term name="Administrative procedure"/>
    <term name="Antitrust law"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Federal Trade Commission"/>
    <term name="Fines (Penalties)"/>
    <term name="Generic drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Health"/>
    <term name="Independent regulatory commissions"/>
    <term name="Injunctions"/>
    <term name="Law"/>
    <term name="Marketing"/>
    <term name="Pharmaceutical research"/>
    <term name="Research and development"/>
    <term name="Restrictive trade practices"/>
    <term name="Science, technology, communications"/>
  </subjects>
  <amendments/>
  <summary>4/4/2001--Introduced.
Prescription Drug Competition Act of 2001 - Requires brand name drug companies and generic drug applicants to file with the Federal Trade Commission and the Secretary of Health and Human Services specified information regarding any agreement regarding the sale or manufacture of a generic drug which the Secretary has determined is the therapeutic equivalent of the brand name drug or for which the applicant seeks a determination of therapeutic equivalence, if such agreement could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.</summary>
</bill>
